Access cutting-edge neuroblastoma treatment through this clinical trial at a research site in Indianapolis. Study-provided care at no cost to qualified participants.
Access neuroblastoma specialists in Indianapolis at no cost
This study follows strict safety protocols and ethical guidelines
All study-related neuroblastoma treatment provided free
Children and adults diagnosed with high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow will be treated for up to 101 weeks with naxitamab and granulocyte-macrophage colony stimulating factor (GM-CSF). Patients will be followed for up to five years after first dose. Naxitamab, also known as hu3F8 is a humanised monoclonal antibody targeting GD2
Sponsor: Y-mAbs Therapeutics
Check if you qualify for this neuroblastoma clinical trial in Indianapolis, IN
If you're searching for neuroblastoma treatment options in Indianapolis, IN, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Indianapolis research site is actively enrolling participants for this clinical trial. You'll receive care from experienced neuroblastoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.